ArticleBreast cancer research : BCR2026
Impact of somatic PIK3CA mutations on clinical outcomes in HER2-positive breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHER2-positive (HER2+) breast cancer (BC) accounts for 15-20% of all BC. Mutations in the PIK3CA gene are found in 25-30% of HER2 + BC cases and have been implicated in tumor progression and endocrine therapy resistance. Recent evidence suggests that a somatic PIK3CA mutation (PIK3CAm) may serve as a marker of early progression in HER2 + metastatic BC. However, its precise prognostic significance across various lines of therapy and disease stages is not fully understood. We therefore aimed to evaluate the impact of PIK3CAm status on clinical outcomes in HER2 + BC patients.
methodsWe conducted a retrospective cohort study using data from the American Association for Cancer Research (AACR) Project GENIE Biopharma Collaborative (BPC). Overall survival (OS), Distant Recurrence-Free Survival (DRFS), and progression-free survival (PFS) were the primary outcomes. We compared patients with and without PIK3CAm and performed survival analysis using Kaplan-Meier methods and Cox proportional hazards models.
resultsWe identified 212 HER2 + patients (150 early-stage and 62 Stage IV), of which 58 had a PIK3CAm. The median OS for the overall cohort was 125.1 months from treatment. Among early-stage patients, PIK3CAm was associated with a longer DRFS from diagnosis (37.7 months [95% CI 28.6-62.6] vs. 22 months [95% CI 16.8-32.8], p = 0.04). In contrast, among patients with Stage IV disease receiving first-line therapy, PIK3CAm was associated with a shorter median PFS (5.5 [95% CI 1.6-32.2] vs. 14.9 months [95% CI 7.2-22.0], p = 0.04). PIK3CAm was not identified as an independent predictor of OS, DRFS, or PFS in univariable or multivariable regression analyses. Within the PIK3CAm subgroup, not having received hormone therapy was the only factor associated with worse survival on multivariable analysis (aHR = 4.51, 95% CI 1.77-11.5).
conclusionPIK3CAm was not found to be associated with worse OS, however it was associated with a shorter PFS among patients receiving first-line therapy, suggesting PIK3CAm could be explored as a predictive biomarker for identifying HER2 + Stage IV patients at higher risk of disease progression. These findings underscore the need for enhanced surveillance and personalized treatment strategies to manage disease progression in this patient subgroup.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.